Premium
Therapeutic potency of Wnt signaling antagonists in the pathogenesis of prostate cancer, current status and perspectives
Author(s) -
Pashirzad Mehran,
Shafiee Mojtaba,
Khazaei Majid,
Fiuji Hamid,
Ryzhikov Mikhail,
Soleimanpour Saman,
Hesari AmirReza,
Avan Amir,
Hassanian Seyed Mahdi
Publication year - 2019
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.27137
Subject(s) - potency , wnt signaling pathway , prostate cancer , pathogenesis , cancer , prostate , medicine , cancer research , signal transduction , pharmacology , oncology , biology , genetics , in vitro
Prostate cancer is a major cause of cancer‐related death in males. Wnt/β‐catenin signaling plays a critical role in the pathogenesis of this disease by regulating angiogenesis, drug resistance, cell proliferation, and apoptosis. Suppression of Wnt canonical or noncanonical signaling pathways via Wnt biological or pharmacological antagonists is a potentially novel therapeutic approach for patients with prostate cancer. This review summarizes the role of Wnt signaling inhibitors in the pathogenesis of prostate cancer for a better understanding and hence a better management of this disease.